Kymera Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical development programs. The company announced positive results from the Phase 1 healthy volunteer trial of its investigational oral degrader, KT-579, which targets the IRF5 transcription factor.
Regarding the KT-579 program, the company reported that the trial met or exceeded study objectives. The data demonstrated a favorable pharmacokinetic profile and robust, sustained IRF5 degradation in blood and skin. In the multiple ascending dose portion of the trial, KT-579 achieved a median degradation of at least 90% across multiple dose levels. The drug also showed significant suppression of disease-relevant biomarkers, including 88% inhibition of TNFα, 87% inhibition of IL-12/23p40, 94% inhibition of IL-1β, and 98% inhibition of IFNβ at Day 14. The safety profile was described as comparable to placebo, with no serious or severe adverse events reported.
Kymera plans to initiate the KT-579 LUMORA Phase 1b trial in lupus patients by early 2027. Additionally, the last patient in the KT-621 BROADEN2 Phase 2b atopic dermatitis trial completed the week 16 visit in October 2026, with topline data expected by year-end. The company also expects to report data from the KT-621 BREADTH Phase 2b asthma trial in late 2027.
Financially, Kymera reported a net loss of $132.0 million for the third quarter of 2026, compared to a net loss of $82.2 million in the prior year. Research and development expenses increased to $128.5 million, driven by investment in the STAT6 program and platform initiatives. General and administrative expenses were $18.7 million. As of September 30, 2026, the company held $1.6 billion in cash, cash equivalents, and investments, providing a cash runway into 2029.
